Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	SPO11 TOP2A TOP2B	8.34e-08	4	56	3	GO:0003918
GeneOntologyMolecularFunction	DNA topoisomerase activity	SPO11 TOP2A TOP2B	1.16e-06	8	56	3	GO:0003916
GeneOntologyMolecularFunction	diphosphoinositol tetrakisphosphate kinase activity	IP6K3 IP6K1	2.31e-05	3	56	2	GO:0052839
GeneOntologyMolecularFunction	inositol 5-diphosphate pentakisphosphate 5-kinase activity	IP6K3 IP6K1	2.31e-05	3	56	2	GO:0052836
GeneOntologyMolecularFunction	nitric-oxide synthase binding	CD74 DMD NOS2	3.10e-05	22	56	3	GO:0050998
GeneOntologyMolecularFunction	inositol hexakisphosphate 3-kinase activity	IP6K3 IP6K1	4.62e-05	4	56	2	GO:0052724
GeneOntologyMolecularFunction	inositol hexakisphosphate 1-kinase activity	IP6K3 IP6K1	4.62e-05	4	56	2	GO:0052723
GeneOntologyMolecularFunction	inositol hexakisphosphate 5-kinase activity	IP6K3 IP6K1	7.68e-05	5	56	2	GO:0000832
GeneOntologyMolecularFunction	diphosphoinositol pentakisphosphate kinase activity	IP6K3 IP6K1	7.68e-05	5	56	2	GO:0000829
GeneOntologyMolecularFunction	inositol hexakisphosphate kinase activity	IP6K3 IP6K1	7.68e-05	5	56	2	GO:0000828
GeneOntologyMolecularFunction	inositol-1,3,4,5,6-pentakisphosphate kinase activity	IP6K3 IP6K1	7.68e-05	5	56	2	GO:0000827
GeneOntologyMolecularFunction	enzyme regulator activity	CCNL2 RAP1GAP IGF1 GBF1 RASA3 STXBP5L DOCK9 MAP3K20 IQSEC1 APC APBA3 RIMS1 NOS2	1.17e-04	1418	56	13	GO:0030234
GeneOntologyMolecularFunction	inositol phosphate kinase activity	IP6K3 IP6K1	4.18e-04	11	56	2	GO:0180030
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	RAP1GAP GBF1 RASA3 STXBP5L DOCK9 IQSEC1 RIMS1	5.16e-04	507	56	7	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	RAP1GAP GBF1 RASA3 STXBP5L DOCK9 IQSEC1 RIMS1	5.16e-04	507	56	7	GO:0030695
GeneOntologyMolecularFunction	protein kinase regulator activity	CCNL2 IGF1 MAP3K20 APC NOS2	7.87e-04	259	56	5	GO:0019887
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine phosphatase activity	PTPRD PTPRN2	1.02e-03	17	56	2	GO:0005001
GeneOntologyMolecularFunction	transmembrane receptor protein phosphatase activity	PTPRD PTPRN2	1.02e-03	17	56	2	GO:0019198
GeneOntologyMolecularFunction	lamin binding	SYNE1 DMD	1.28e-03	19	56	2	GO:0005521
GeneOntologyMolecularFunction	cell adhesion molecule binding	FLNB IGF1 PTPRD DOCK9 APC DMD NOS2	1.37e-03	599	56	7	GO:0050839
GeneOntologyMolecularFunction	kinase regulator activity	CCNL2 IGF1 MAP3K20 APC NOS2	1.63e-03	305	56	5	GO:0019207
GeneOntologyMolecularFunction	amyloid-beta binding	CALCR APBA3 CD74	2.95e-03	102	56	3	GO:0001540
GeneOntologyMolecularFunction	phosphatidylinositol-3,5-bisphosphate binding	MAPKAP1 GBF1	3.41e-03	31	56	2	GO:0080025
GeneOntologyMolecularFunction	ATP-dependent activity, acting on DNA	SPO11 TOP2A TOP2B	5.45e-03	127	56	3	GO:0008094
GeneOntologyMolecularFunction	phosphotransferase activity, phosphate group as acceptor	IP6K3 IP6K1	5.91e-03	41	56	2	GO:0016776
GeneOntologyMolecularFunction	catalytic activity, acting on DNA	SPO11 TDP1 TOP2A TOP2B	6.23e-03	262	56	4	GO:0140097
GeneOntologyBiologicalProcess	anterograde trans-synaptic signaling	GABRR2 IGF1 PTPRD PTPRN2 STXBP5L SYNE1 IQSEC1 APBA3 DGKE RIMS1 GRIN3A DMD	5.93e-06	931	56	12	GO:0098916
GeneOntologyBiologicalProcess	chemical synaptic transmission	GABRR2 IGF1 PTPRD PTPRN2 STXBP5L SYNE1 IQSEC1 APBA3 DGKE RIMS1 GRIN3A DMD	5.93e-06	931	56	12	GO:0007268
GeneOntologyBiologicalProcess	trans-synaptic signaling	GABRR2 IGF1 PTPRD PTPRN2 STXBP5L SYNE1 IQSEC1 APBA3 DGKE RIMS1 GRIN3A DMD	6.47e-06	939	56	12	GO:0099537
GeneOntologyBiologicalProcess	positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	TOP2A TOP2B	7.24e-06	2	56	2	GO:0045870
GeneOntologyBiologicalProcess	synaptic signaling	GABRR2 IGF1 PTPRD PTPRN2 STXBP5L SYNE1 IQSEC1 APBA3 DGKE RIMS1 GRIN3A DMD	9.56e-06	976	56	12	GO:0099536
GeneOntologyCellularComponent	exocytic vesicle	IGF1 PTPRN2 SLC6A17 IQSEC1 APC DMD	2.09e-04	320	56	6	GO:0070382
GeneOntologyCellularComponent	glutamatergic synapse	SCN11A IGF1 PTPRD SLC6A17 IQSEC1 APC DGKE RIMS1 GRIN3A	2.96e-04	817	56	9	GO:0098978
GeneOntologyCellularComponent	transport vesicle	IGF1 PTPRN2 SLC6A17 IQSEC1 APC CD74 DMD	4.52e-04	519	56	7	GO:0030133
GeneOntologyCellularComponent	presynapse	SCN11A PTPRD PTPRN2 SLC6A17 IQSEC1 APC RIMS1 GRIN3A DMD	5.35e-04	886	56	9	GO:0098793
GeneOntologyCellularComponent	synaptic membrane	GABRR2 SCN11A PTPRD SYNE1 RIMS1 GRIN3A DMD	8.98e-04	583	56	7	GO:0097060
GeneOntologyCellularComponent	GABA-ergic synapse	GABRR2 SLC6A17 RIMS1 DMD	9.76e-04	164	56	4	GO:0098982
GeneOntologyCellularComponent	transport vesicle membrane	PTPRN2 SLC6A17 APC CD74 DMD	1.11e-03	293	56	5	GO:0030658
GeneOntologyCellularComponent	synaptic vesicle	PTPRN2 SLC6A17 IQSEC1 APC DMD	1.24e-03	300	56	5	GO:0008021
GeneOntologyCellularComponent	exocytic vesicle membrane	PTPRN2 SLC6A17 APC DMD	1.35e-03	179	56	4	GO:0099501
GeneOntologyCellularComponent	synaptic vesicle membrane	PTPRN2 SLC6A17 APC DMD	1.35e-03	179	56	4	GO:0030672
GeneOntologyCellularComponent	somatodendritic compartment	FLNB SCN11A RAP1GAP IGF1 CALCR SYNE1 APC APBA3 GRIN3A DMD	1.41e-03	1228	56	10	GO:0036477
GeneOntologyCellularComponent	postsynapse	GABRR2 SYNE1 SLC6A17 IQSEC1 APC APBA3 RIMS1 GRIN3A DMD	1.43e-03	1018	56	9	GO:0098794
GeneOntologyCellularComponent	neuronal cell body	FLNB SCN11A RAP1GAP IGF1 CALCR APC GRIN3A DMD	1.63e-03	835	56	8	GO:0043025
GeneOntologyCellularComponent	membrane protein complex	GABRR2 SCN11A IGF1 CALCR STXBP5L SYNE1 APC CD74 GRIN3A DMD NDUFS2	1.83e-03	1498	56	11	GO:0098796
GeneOntologyCellularComponent	cell body	FLNB SCN11A RAP1GAP IGF1 CALCR APC GRIN3A DMD	3.16e-03	929	56	8	GO:0044297
Domain	DNA_topoisoIV	TOP2A TOP2B	8.51e-06	2	55	2	PF00521
Domain	Topo_IIA_A/C_ab	TOP2A TOP2B	8.51e-06	2	55	2	IPR013758
Domain	Topo_IIA_A_a	TOP2A TOP2B	8.51e-06	2	55	2	IPR013757
Domain	Topo_IIA_cen_dom	TOP2A TOP2B	8.51e-06	2	55	2	IPR013759
Domain	-	TOP2A TOP2B	8.51e-06	2	55	2	3.40.50.670
Domain	DTHCT	TOP2A TOP2B	8.51e-06	2	55	2	IPR012542
Domain	TOP4c	TOP2A TOP2B	8.51e-06	2	55	2	SM00434
Domain	TOP2c	TOP2A TOP2B	8.51e-06	2	55	2	SM00433
Domain	Topo_IIA-like_dom	TOP2A TOP2B	8.51e-06	2	55	2	IPR013760
Domain	Topo_IIA_bsu_dom2	TOP2A TOP2B	8.51e-06	2	55	2	IPR013506
Domain	DTHCT	TOP2A TOP2B	8.51e-06	2	55	2	PF08070
Domain	DNA_gyraseB	TOP2A TOP2B	8.51e-06	2	55	2	PF00204
Domain	-	TOP2A TOP2B	8.51e-06	2	55	2	1.10.268.10
Domain	TOPRIM_C	TOP2A TOP2B	8.51e-06	2	55	2	IPR031660
Domain	TOPRIM_C	TOP2A TOP2B	8.51e-06	2	55	2	PF16898
Domain	-	TOP2A TOP2B	8.51e-06	2	55	2	3.90.199.10
Domain	TopoIIA_CS	TOP2A TOP2B	8.51e-06	2	55	2	IPR018522
Domain	Topo_IIA_A/C	TOP2A TOP2B	8.51e-06	2	55	2	IPR002205
Domain	Topo_IIA	TOP2A TOP2B	8.51e-06	2	55	2	IPR001241
Domain	TOPOISOMERASE_II	TOP2A TOP2B	8.51e-06	2	55	2	PS00177
Domain	-	TOP2A TOP2B	2.55e-05	3	55	2	3.30.1360.40
Domain	Arg_repress_C-like	TOP2A TOP2B	2.55e-05	3	55	2	IPR024946
Domain	Actinin_actin-bd_CS	FLNB SYNE1 DMD	4.10e-05	23	55	3	IPR001589
Domain	ACTININ_2	FLNB SYNE1 DMD	4.10e-05	23	55	3	PS00020
Domain	ACTININ_1	FLNB SYNE1 DMD	4.10e-05	23	55	3	PS00019
Domain	Toprim_domain	TOP2A TOP2B	5.09e-05	4	55	2	IPR006171
Domain	Toprim	TOP2A TOP2B	5.09e-05	4	55	2	PF01751
Domain	TOPRIM	TOP2A TOP2B	5.09e-05	4	55	2	PS50880
Domain	IPK	IP6K3 IP6K1	1.77e-04	7	55	2	PF03770
Domain	IPK	IP6K3 IP6K1	1.77e-04	7	55	2	IPR005522
Domain	-	GBF1 IQSEC1	8.72e-04	15	55	2	1.10.1000.11
Domain	Sec7	GBF1 IQSEC1	8.72e-04	15	55	2	PF01369
Domain	Sec7_alpha_orthog	GBF1 IQSEC1	8.72e-04	15	55	2	IPR023394
Domain	CH	FLNB SYNE1 DMD	9.28e-04	65	55	3	SM00033
Domain	Sec7	GBF1 IQSEC1	9.95e-04	16	55	2	SM00222
Domain	SEC7	GBF1 IQSEC1	9.95e-04	16	55	2	PS50190
Domain	Sec7_dom	GBF1 IQSEC1	9.95e-04	16	55	2	IPR000904
Domain	CH	FLNB SYNE1 DMD	1.15e-03	70	55	3	PF00307
Domain	-	FLNB SYNE1 DMD	1.20e-03	71	55	3	1.10.418.10
Domain	HATPase_c	TOP2A TOP2B	1.26e-03	18	55	2	SM00387
Domain	CH	FLNB SYNE1 DMD	1.30e-03	73	55	3	PS50021
Domain	CH-domain	FLNB SYNE1 DMD	1.40e-03	75	55	3	IPR001715
Domain	HATPase_c	TOP2A TOP2B	1.41e-03	19	55	2	PF02518
Domain	-	TOP2A TOP2B	1.56e-03	20	55	2	3.30.565.10
Domain	-	TOP2A TOP2B	1.72e-03	21	55	2	3.30.230.10
Domain	HATPase_C	TOP2A TOP2B	1.72e-03	21	55	2	IPR003594
Domain	Ribosomal_S5_D2-typ_fold_subgr	TOP2A TOP2B	1.89e-03	22	55	2	IPR014721
Domain	Spectrin	SYNE1 DMD	2.07e-03	23	55	2	PF00435
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	FLNB MYH13 SYNE1 DMD TOP2A TOP2B	2.13e-06	234	56	6	36243803
Pubmed	DNA topoisomerase II is dispensable for oocyte meiotic resumption but is essential for meiotic chromosome condensation and separation in mice.	TOP2A TOP2B	2.55e-06	2	56	2	24048577
Pubmed	Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.	TOP2A TOP2B	2.55e-06	2	56	2	19222228
Pubmed	Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.	TOP2A TOP2B	2.55e-06	2	56	2	2555055
Pubmed	Characterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutation.	TOP2A TOP2B	2.55e-06	2	56	2	1331984
Pubmed	Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.	TOP2A TOP2B	2.55e-06	2	56	2	31106979
Pubmed	A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus.	TOP2A TOP2B	2.55e-06	2	56	2	16091284
Pubmed	Mining topoisomerase isoforms in gastric cancer.	TOP2A TOP2B	2.55e-06	2	56	2	32535049
Pubmed	Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.	TOP2A TOP2B	2.55e-06	2	56	2	1380833
Pubmed	Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.	DMD NOS2	2.55e-06	2	56	2	18996917
Pubmed	Involvement of human topoisomerase II isoforms in HIV-1 reverse transcription.	TOP2A TOP2B	2.55e-06	2	56	2	23399433
Pubmed	Enhanced processing of UVA-irradiated DNA by human topoisomerase II in living cells.	TOP2A TOP2B	2.55e-06	2	56	2	15044480
Pubmed	C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.	TOP2A TOP2B	2.55e-06	2	56	2	17526531
Pubmed	A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo.	IGF1 DMD	2.55e-06	2	56	2	20179101
Pubmed	Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse.	APC NOS2	2.55e-06	2	56	2	11606502
Pubmed	DNA topoisomerase II distribution in mouse preimplantation embryos.	TOP2A TOP2B	2.55e-06	2	56	2	11835579
Pubmed	Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.	TOP2A TOP2B	2.55e-06	2	56	2	2556712
Pubmed	The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis.	APC NOS2	2.55e-06	2	56	2	16329147
Pubmed	Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase IIalpha.	TOP2A TOP2B	2.55e-06	2	56	2	10473615
Pubmed	Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy.	IGF1 DMD	2.55e-06	2	56	2	16716629
Pubmed	Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.	TOP2A TOP2B	2.55e-06	2	56	2	9224616
Pubmed	DNA damage response during chromatin remodeling in elongating spermatids of mice.	TOP2A TOP2B	2.55e-06	2	56	2	18032420
Pubmed	Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants.	TOP2A TOP2B	2.55e-06	2	56	2	22111588
Pubmed	Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.	TOP2A TOP2B	2.55e-06	2	56	2	17578914
Pubmed	Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.	TOP2A TOP2B	2.55e-06	2	56	2	1309226
Pubmed	The ability of GAP1IP4BP to function as a Rap1 GTPase-activating protein (GAP) requires its Ras GAP-related domain and an arginine finger rather than an asparagine thumb.	RAP1GAP RASA3	2.55e-06	2	56	2	19433443
Pubmed	Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival.	APC NOS2	2.55e-06	2	56	2	17096347
Pubmed	Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance.	TOP2A TOP2B	2.55e-06	2	56	2	14596941
Pubmed	Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.	TOP2A TOP2B	2.55e-06	2	56	2	17361331
Pubmed	Inositol hexakisphosphate kinases differentially regulate trafficking of vesicular glutamate transporters 1 and 2.	IP6K3 IP6K1	2.55e-06	2	56	2	35936490
Pubmed	Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.	TOP2A TOP2B	2.55e-06	2	56	2	10095062
Pubmed	Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.	TOP2A TOP2B	2.55e-06	2	56	2	14996935
Pubmed	Structural organization of the human TOP2A and TOP2B genes.	TOP2A TOP2B	2.55e-06	2	56	2	9795238
Pubmed	The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues.	TOP2A TOP2B	2.55e-06	2	56	2	8241259
Pubmed	Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice.	IGF1 DMD	2.55e-06	2	56	2	11927606
Pubmed	Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells.	TOP2A TOP2B	2.55e-06	2	56	2	11927602
Pubmed	Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.	TOP2A TOP2B	2.55e-06	2	56	2	17182034
Pubmed	Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons.	TOP2A TOP2B	2.55e-06	2	56	2	28700616
Pubmed	Predictors and mechanisms of epilepsy occurrence in cerebral gliomas: What to look for in clinicopathology.	TOP2A TOP2B	2.55e-06	2	56	2	28087392
Pubmed	Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.	TOP2A TOP2B	2.55e-06	2	56	2	28472494
Pubmed	Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.	TOP2A TOP2B	2.55e-06	2	56	2	32218491
Pubmed	Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.	APC CD74	2.55e-06	2	56	2	19269807
Pubmed	Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2.	TOP2A TOP2B	2.55e-06	2	56	2	30169847
Pubmed	The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.	TOP2A TOP2B	2.55e-06	2	56	2	9155056
Pubmed	A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.	TOP2A TOP2B	2.55e-06	2	56	2	16712776
Pubmed	Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms.	TOP2A TOP2B	2.55e-06	2	56	2	8710863
Pubmed	Distinct expression patterns for type II topoisomerases IIA and IIB in the early foetal human telencephalon.	TOP2A TOP2B	2.55e-06	2	56	2	26612825
Pubmed	iNOS ablation does not improve specific force of the extensor digitorum longus muscle in dystrophin-deficient mdx4cv mice.	DMD NOS2	2.55e-06	2	56	2	21738735
Pubmed	Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.	APC TOP2A	2.55e-06	2	56	2	18632987
Pubmed	Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production.	APC NOS2	2.55e-06	2	56	2	11731407
Pubmed	Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.	TOP2A TOP2B	2.55e-06	2	56	2	8299728
Pubmed	Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.	TOP2A TOP2B	7.63e-06	3	56	2	11136718
Pubmed	Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.	TDP1 TOP2A	7.63e-06	3	56	2	22375014
Pubmed	Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).	TOP2A TOP2B	7.63e-06	3	56	2	24808172
Pubmed	Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.	TOP2A TOP2B	7.63e-06	3	56	2	12821127
Pubmed	Ligand-specific antibodies to insulin-like growth factors suppress intestinal polyp formation in Apc+/- mice.	IGF1 APC	7.63e-06	3	56	2	20103605
Pubmed	Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.	TOP2A TOP2B	7.63e-06	3	56	2	10666337
Pubmed	Nucleophagy contributes to genome stability through degradation of type II topoisomerases A and B and nucleolar components.	TOP2A TOP2B	7.63e-06	3	56	2	36633090
Pubmed	Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.	TOP2A TOP2B	7.63e-06	3	56	2	16611985
Pubmed	Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice.	RAP1GAP APC	7.63e-06	3	56	2	8978063
Pubmed	Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.	TOP2A TOP2B	7.63e-06	3	56	2	17567603
Pubmed	Identification and characterization of a novel inositol hexakisphosphate kinase.	IP6K3 IP6K1	7.63e-06	3	56	2	11502751
Pubmed	Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation.	APC NOS2	7.63e-06	3	56	2	22893683
Pubmed	MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease by regulating inducible nitric-oxide synthase.	IGF1 NOS2	7.63e-06	3	56	2	32474958
Pubmed	DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism.	TOP2A TOP2B	7.63e-06	3	56	2	23466610
Pubmed	Elevated incidence of polyp formation in APC(Min/⁺)Msh2⁻/⁻ mice is independent of nitric oxide-induced DNA mutations.	APC NOS2	7.63e-06	3	56	2	23741483
Pubmed	BRAG2a, a Guanine Nucleotide Exchange Factor for Arf6, Is a Component of the Dystrophin-Associated Glycoprotein Complex at the Photoreceptor Terminal.	IQSEC1 DMD	7.63e-06	3	56	2	28744553
Pubmed	Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.	TOP2A TOP2B	7.63e-06	3	56	2	9049244
Pubmed	Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1.	APC NOS2	1.52e-05	4	56	2	23016931
Pubmed	SUMO-1 conjugation to human DNA topoisomerase II isozymes.	TOP2A TOP2B	1.52e-05	4	56	2	10862613
Pubmed	iNOS is not responsible for RyR1 S-nitrosylation in mdx mice with truncated dystrophin.	DMD NOS2	1.52e-05	4	56	2	32693782
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	STXBP5L SLC6A17 DOCK9 IQSEC1 APC RIMS1	2.01e-05	347	56	6	17114649
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	RLF FLNB IGF1 RASA3 PTPRN2 STXBP5L ZFP64 ZNF362 RIMS1 CPT1A ERMARD	2.15e-05	1489	56	11	28611215
Pubmed	Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer.	MAPKAP1 WEE1 MAP3K20 APC	2.28e-05	102	56	4	15778465
Pubmed	Differing roles of mitochondrial nitric oxide synthase in cardiomyocytes and urothelial cells.	DMD NOS2	2.54e-05	5	56	2	14684357
Pubmed	Histone deacetylase interacts directly with DNA topoisomerase II.	TOP2A TOP2B	2.54e-05	5	56	2	11062478
Pubmed	TRIM65 regulates microRNA activity by ubiquitination of TNRC6.	BYSL IQSEC1 APBA3 NDUFS2 TOP2A TOP2B	2.63e-05	364	56	6	24778252
Pubmed	Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.	TOP2A TOP2B	3.80e-05	6	56	2	31202577
Pubmed	Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression.	APC ZNF292	3.80e-05	6	56	2	25559195
Pubmed	High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity.	APC CPT1A	3.80e-05	6	56	2	34107251
Pubmed	Nitric-oxide synthase 2 interacts with CD74 and inhibits its cleavage by caspase during dendritic cell development.	CD74 NOS2	3.80e-05	6	56	2	18003616
Pubmed	ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.	MEMO1 APC	5.32e-05	7	56	2	20937854
Pubmed	Topoisomerase II regulates the maintenance of DNA methylation.	TOP2A TOP2B	5.32e-05	7	56	2	25451918
Pubmed	GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.	GBF1 IQSEC1	5.32e-05	7	56	2	18084281
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	MEMO1 RLF FLNB RASA3 MAP3K20 BYSL IQSEC1 ALDH18A1 TOP2A TOP2B	5.35e-05	1353	56	10	29467282
Pubmed	Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.	PTPRN2 IQSEC1 APC DGKE CPT1A NDUFS2	6.64e-05	430	56	6	32581705
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	MAPKAP1 FSIP2 RAP1GAP GBF1 WEE1 MAP3K20 IQSEC1 APC	6.78e-05	861	56	8	36931259
Pubmed	A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation.	TOP2A TOP2B	7.09e-05	8	56	2	33188014
Pubmed	Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.	TOP2A TOP2B	9.10e-05	9	56	2	18394993
Pubmed	A PAK5-DNPEP-USP4 axis dictates breast cancer growth and metastasis.	DMD TOP2A	9.10e-05	9	56	2	31219614
Pubmed	Genetic modifiers of muscular dystrophy: implications for therapy.	IGF1 DMD	9.10e-05	9	56	2	16916601
Pubmed	Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia.	MEMO1 SYNE1 CEP57L1 DMD	1.05e-04	151	56	4	17043677
Pubmed	Genome-wide association study of co-occurring anxiety in major depression.	PTPRD DMD	1.14e-04	10	56	2	24047446
Pubmed	Interplay between Pitx2 and Pax7 temporally governs specification of extraocular muscle stem cells.	CALCR DMD	1.14e-04	10	56	2	38875306
Pubmed	Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney.	MAPKAP1 IGF1	1.14e-04	10	56	2	21413931
Pubmed	Two dominant host resistance genes to pre-B lymphoma in wild-derived inbred mouse strain MSM/Ms.	APC CD74	1.14e-04	10	56	2	8706013
Pubmed	Inositol hexakisphosphate kinase 3 promotes focal adhesion turnover via interactions with dynein intermediate chain 2.	IP6K3 IP6K1	1.39e-04	11	56	2	30718399
Pubmed	Hesr1 and Hesr3 are essential to generate undifferentiated quiescent satellite cells and to maintain satellite cell numbers.	CALCR DMD	1.39e-04	11	56	2	21989910
Pubmed	A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.	WEE1 APC TOP2A	1.61e-04	65	56	3	27453043
Pubmed	Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation.	STXBP5L DMD ZNF292	2.09e-04	71	56	3	33541421
GeneFamily	Topoisomerases	TOP2A TOP2B	5.12e-05	6	34	2	1050
GeneFamily	Protein tyrosine phosphatases, receptor type	PTPRD PTPRN2	7.05e-04	21	34	2	813
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	RLF ZNF142 ZFP64 ZNF362 ZNF292	1.04e-02	718	34	5	28
Coexpression	BILBAN_B_CLL_LPL_UP	FLNB ZFP64 DMD CPT1A	1.08e-05	64	56	4	M19930
Coexpression	ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_DN	FLNB RASA3 WEE1 SYNE1 DOCK9 ALDH18A1 IP6K1 TDP1 TOP2B ZNF292	4.98e-05	1012	56	10	M40864
Coexpression	GSE29164_DAY3_VS_DAY7_UNTREATED_MELANOMA_DN	B3GNT5 RASA3 SYNE1 ERMARD PID1	6.69e-05	199	56	5	M8487
Coexpression	GSE23308_WT_VS_MINERALCORTICOID_REC_KO_MACROPHAGE_CORTICOSTERONE_TREATED_DN	RLF ODF4 BYSL APBA3 ZNF292	6.85e-05	200	56	5	M7748
Coexpression	GSE11961_MEMORY_BCELL_DAY40_VS_GERMINAL_CENTER_BCELL_DAY40_DN	GABRR2 RAP1GAP SYNE1 IQSEC1 SPO11	6.85e-05	200	56	5	M9382
Coexpression	GSE12198_CTRL_VS_LOW_IL2_STIM_NK_CELL_UP	RLF CEP57L1 IQSEC1 SPO11 DGKE	6.85e-05	200	56	5	M7073
Coexpression	GSE27786_CD4_TCELL_VS_NKCELL_UP	RLF GABRR2 FLNB ZNF362 ZNF292	6.85e-05	200	56	5	M4822
Coexpression	GSE35685_CD34POS_CD10NEG_CD62LPOS_VS_CD34POS_CD10POS_BONE_MARROW_UP	FLNB IGF1 RASA3 ZNF362 CPT1A	6.85e-05	200	56	5	M9080
Coexpression	GSE17580_UNINFECTED_VS_S_MANSONI_INF_TEFF_UP	MAPKAP1 ZNF142 BYSL IQSEC1 CD74	6.85e-05	200	56	5	M3675
Coexpression	GSE21670_UNTREATED_VS_IL6_TREATED_CD4_TCELL_DN	SYNE1 SPO11 CD74 CPT1A ZNF292	6.85e-05	200	56	5	M7441
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	IGF1 PTPRD MAP3K20 RIMS1 PID1	3.68e-06	186	56	5	7def03dd856b765bd3f493288641981c4f7fd26e
ToppCell	facs-Pancreas-Endocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLNB GBF1 PTPRN2 DGKE GMPR	4.30e-06	192	56	5	5b7093d5af5ae7b0e6d3a464cc56272440ecedad
ToppCell	RV-09._Endothelium_I\|RV / Chamber and Cluster_Paper	FLNB SYNE1 DOCK9 CD74 DGKE	4.52e-06	194	56	5	7b408096e717f2327c12aea35a8d5fc4621d3b06
ToppCell	droplet-Thymus-nan-24m-Lymphocytic-immature_T_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GABRR2 IGF1 SPO11 CD74	2.31e-05	132	56	4	9936078c328b1e1d59f9dfdd69d36926a0cdaf0d
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell_cycling-Cycling_Connecting_Tubule_Cell_S-high\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SLC6A17 RIMS1 GRIN3A TOP2A	2.83e-05	139	56	4	c9bf98bed77415a1438f3f9e441a1346e75c26b0
ToppCell	COVID-19-kidney-Technical/muscle_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	PTPRN2 STXBP5L RIMS1 DMD	4.78e-05	159	56	4	5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c13-MKI67-CCL5_l\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	IGF1 BYSL TDP1 TOP2A	6.20e-05	170	56	4	12aa9bdb18f3bf6da2a25984d08fe9497e5570ed
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(Neuron.Gad1Gad2.Sst-Nr2f2)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	SCN11A MYH13 ODF4	6.56e-05	62	56	3	9db88da996b9977f5a89afe505cd55e7b5324bc9
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Sst-Inhibitory_Neuron.Gad1Gad2.Sst-Nr2f2_(Neuron.Gad1Gad2.Sst-Nr2f2)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	SCN11A MYH13 ODF4	6.56e-05	62	56	3	461d280a1b955033186cfc326f9ace85b4a53c54
ToppCell	COVID-19_Convalescent\|World / Disease Group and Platelet Clusters	MEMO1 FLNB ZNF142 DMD	6.94e-05	175	56	4	e9b1faa4c85537f30306619a2f3ada6c8ef0ac6c
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	IGF1 RIMS1 GRIN3A DMD	7.25e-05	177	56	4	c9b02a2e1ff2aa18c37e88a53b06a5b696a442ae
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD CEP57L1 DMD TOP2B	7.25e-05	177	56	4	426a9845df7fd13b02e744532c336c60bc4d4a22
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_C\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	FLNB GMPR CPT1A PID1	7.41e-05	178	56	4	50bb1f2c6a8d050ff2af217fd76c3b1b7b4a4a69
ToppCell	droplet-Kidney-KIDNEY-1m-Lymphocytic-B_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	B3GNT5 RASA3 ALDH18A1 CD74	7.90e-05	181	56	4	d90faa6115b408c9fbca61fc90ff951e070754ba
ToppCell	facs-Large_Intestine-Distal-24m-Epithelial-nan\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCN11A RAP1GAP B3GNT5 GMPR	7.90e-05	181	56	4	75340f0c06977c88f9d2e56265f4aa84d706d2c6
ToppCell	Epithelial-lung_neuroendocrine_cell_(PNEC)\|World / Lineage, Cell type, age group and donor	PTPRN2 STXBP5L SLC6A17 RIMS1	8.07e-05	182	56	4	57bf4ffb304324e2e392e196336a530d9f78fe0d
ToppCell	droplet-Kidney-KIDNEY-1m-Epithelial-Epcam_____kidney_distal_convoluted_tubule_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BSND IGF1 ODF4 GRIN3A	8.25e-05	183	56	4	f3728b1a51951c7349f77a3e4d2671ca3a8d2a44
ToppCell	343B-Lymphocytic-CD4_T-cell-Proliferating_T_cell\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	CMBL B3GNT5 GMPR TOP2A	8.25e-05	183	56	4	f03d87b556a3d50360d4eb6126b3466fe7266677
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD STXBP5L SLC6A17 DMD	8.42e-05	184	56	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD STXBP5L SLC6A17 DMD	8.42e-05	184	56	4	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD STXBP5L SLC6A17 DMD	8.42e-05	184	56	4	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	droplet-Kidney-KIDNEY-1m-Epithelial-kidney_distal_convoluted_tubule_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BSND IGF1 ODF4 GRIN3A	8.42e-05	184	56	4	8939b6d795992775df0ff58ed1ec9d421a00bcc4
ToppCell	facs-Brain_Non-Myeloid-Cerebellum\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STXBP5L SLC6A17 CD74 RIMS1	8.60e-05	185	56	4	c083a4974590b9ed3ecafedd3e9cdebc5047fe39
ToppCell	LPS_only-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SYNE1 MAP3K20 RIMS1 DMD	8.60e-05	185	56	4	e64e8c98dd88d91f6501d3fb10b60fd2f3c90af3
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PTPRN2 STXBP5L SLC6A17 RIMS1	8.78e-05	186	56	4	b45cce768e4bf91da194fd9660cab7520dfb15ac
ToppCell	3'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC-Fetal_arterial_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SCN11A DOCK9 DGKE NOS2	8.96e-05	187	56	4	25efb82afe863a853ecdd781ad89026c993aaa67
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_ASM_(13)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	IGF1 SLC6A17 MAP3K20 DMD	9.15e-05	188	56	4	74f7d216209cabdc96b2d46685b0ae017fdcc8fc
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGF1 GRIN3A DMD PID1	9.15e-05	188	56	4	ce85a56ac27a6432421dde93a1bafa8b943244b9
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	B3GNT5 RASA3 IQSEC1 CD74	9.15e-05	188	56	4	1f07e3ab87173426fe0c429f5c084fb3425effd3
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	B3GNT5 RASA3 IQSEC1 CD74	9.15e-05	188	56	4	85746f95319e494efdc1bbc24331698688d3a900
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PTPRN2 STXBP5L SLC6A17 RIMS1	9.15e-05	188	56	4	c4c3b21ab723b0e9beff9ec84f8d68485f771528
ToppCell	facs-Trachea-nan-3m-Mesenchymal-smooth_muscle_cell_of_trachea\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CALCR SLC6A17 TAF7L DMD	9.15e-05	188	56	4	794fc1d9a726945c42f7eac221eed938309b47a9
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	IGF1 SLC6A17 MAP3K20 RIMS1	9.34e-05	189	56	4	b6d5dec55bf352f6ae19d8f488ae70aa10fb9a8f
ToppCell	facs-Skin-nan-18m-Epithelial-Basal_IFE\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RASA3 WEE1 SYNE1 TAF7L	9.34e-05	189	56	4	6c71e81373cb7822de23c193a6350b6df9f567bc
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_ASM_(13)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	IGF1 SLC6A17 MAP3K20 DMD	9.34e-05	189	56	4	da9ecc0d7b81c1901f30f97bb44112dc85444a66
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RASA3 SYNE1 MAP3K20 DMD	9.53e-05	190	56	4	1121eb607a984c59fbffe7220837fc178745aa55
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RASA3 SYNE1 MAP3K20 DMD	9.53e-05	190	56	4	048b581e3f7ea9fc2f87c0532974bba85c7292c2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGF1 GRIN3A DMD PID1	9.53e-05	190	56	4	efb757f11c2809e66ddb48a5c84f5433f111cb7c
ToppCell	facs-Pancreas-Endocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLNB PTPRN2 DGKE GMPR	9.73e-05	191	56	4	f76f3f5c7902a3659d8cbe470f96ce57c8a6744d
ToppCell	droplet-Kidney-nan-3m-Epithelial-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BSND RAP1GAP SLC6A17 CPT1A	9.73e-05	191	56	4	297bc79adc5fef211497819b4861b52cd26ac754
ToppCell	droplet-Kidney-nan-3m-Epithelial-Epcam____thick_ascending_tube_S_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BSND RAP1GAP SLC6A17 CPT1A	9.73e-05	191	56	4	e1ec165ba6578cefd88895e7e183190e79f733a4
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLNB GBF1 PTPRN2 GMPR	1.01e-04	193	56	4	471e65f02937bc18d7c5facdacdf1df58cf0f839
ToppCell	severe-low-quality_cells\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	MEMO1 SYNE1 DGKE ZNF292	1.01e-04	193	56	4	9337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLNB GBF1 PTPRN2 GMPR	1.01e-04	193	56	4	fe451b3295d77b2bd1ac25cf29310c85835a45fe
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-MYL4+_SMC\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	IGF1 SLC6A17 MAP3K20 RIMS1	1.05e-04	195	56	4	dba2a87efd7e067c094c4b367feb4138cab62735
ToppCell	LA-09._Endothelium_I\|World / Chamber and Cluster_Paper	FLNB SYNE1 DOCK9 CD74	1.05e-04	195	56	4	fc95457a298b5d0dab687d9ee7e225a7f7b9a0d4
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 STXBP5L SYNE1 RIMS1	1.07e-04	196	56	4	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	367C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)\|Macrophage / Donor, Lineage, Cell class and subclass (all cells)	IGF1 SYNE1 CD74 PID1	1.07e-04	196	56	4	e8c4eeb4b6c6d9bccca2adb942d4cfbaab39636c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 MAP3K20 DMD PID1	1.10e-04	197	56	4	85a8f1d18e0dd1d31341f5131eecd217553bf042
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SYNE1 MAP3K20 DMD PID1	1.10e-04	197	56	4	e8e3ba791dfaa0fab35e0329a5e34376f9ee6143
ToppCell	LA-09._Endothelium_I\|LA / Chamber and Cluster_Paper	FLNB SYNE1 DOCK9 CD74	1.10e-04	197	56	4	ab6d1ab586a188597a39854ef980b8955ebcc645
ToppCell	3'_v3-Lung-Myeloid_Mac-Intermediate_macrophages\|Lung / Manually curated celltypes from each tissue	FLNB B3GNT5 MAP3K20 PID1	1.10e-04	197	56	4	bcb4dc17dae705bd84ea6a2842d6b107562baeb7
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RASA3 SYNE1 MAP3K20 DMD	1.10e-04	197	56	4	9b480f9c799a244bfee64487abd8a1bf07c9a3a2
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-myocytic-SMC_(PLPP2+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGF1 MAP3K20 RIMS1 DMD	1.10e-04	197	56	4	f4f686d20821af3e6f859b96edc31827a430e3de
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 STXBP5L SYNE1 RIMS1	1.12e-04	198	56	4	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 STXBP5L SYNE1 RIMS1	1.12e-04	198	56	4	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 STXBP5L SYNE1 RIMS1	1.12e-04	198	56	4	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RASA3 SYNE1 MAP3K20 DMD	1.12e-04	198	56	4	a860246bcea847249a78fd2e86ed8e04371060db
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 STXBP5L SYNE1 RIMS1	1.12e-04	198	56	4	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Newborn-35\|World / Primary Cells by Cluster	PTPRD PID1 TOP2B ZNF292	1.12e-04	198	56	4	de5214a85fe017eb23d4aa8af624464f062ec57e
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	IGF1 SYNE1 MAP3K20 DMD	1.14e-04	199	56	4	e9820d5fb4e8b46973c4c50ac5db8fb4a1bf603b
ToppCell	3'_v3-GI_small-bowel-Myeloid_Mac\|GI_small-bowel / Manually curated celltypes from each tissue	IGF1 B3GNT5 CD74 PID1	1.14e-04	199	56	4	8990a3d69e24cb3aaba9d6def3d0be9ee973436d
ToppCell	3'_v3-GI_small-bowel-Myeloid_Mac-Intestinal_macrophages\|GI_small-bowel / Manually curated celltypes from each tissue	IGF1 B3GNT5 CD74 PID1	1.14e-04	199	56	4	96070b5ffcbab4952970f43b536969ddd2ca5d14
ToppCell	ILEUM-non-inflamed-(8)_Fibroblast-(8)_Fibroblasts\|(8)_Fibroblast / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	FLNB IGF1 CD74 PID1	1.14e-04	199	56	4	56d72da6a5fab9cbb2975fe6f87a631debaba6a8
ToppCell	Control-Control-Myeloid-immature_Neutrophil\|Control / Disease, condition lineage and cell class	RLF GBF1 B3GNT5 TOP2A	1.16e-04	200	56	4	118321ac443feb42aee171baccfc4610f00a8822
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	IGF1 SYNE1 MAP3K20 DMD	1.16e-04	200	56	4	9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	PTPRN2 STXBP5L SYNE1 RIMS1	1.16e-04	200	56	4	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	IGF1 SYNE1 MAP3K20 DMD	1.16e-04	200	56	4	87827041663013f5e7273168dc8709d69840e7ce
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast\|Control_saline / Treatment groups by lineage, cell group, cell type	IGF1 MAP3K20 RIMS1 DMD	1.16e-04	200	56	4	a799fc7bb83ad0524362cb5010df949741fb7bf3
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	IGF1 SYNE1 MAP3K20 DMD	1.16e-04	200	56	4	c596a53c0b63c9deaac7d99fcbdd94ecfa96b86c
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	IGF1 SYNE1 MAP3K20 DMD	1.16e-04	200	56	4	8988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e
ToppCell	Kidney\|World / Skin and Kidney Cells in Lupus Nephritis Patients.	BSND CMBL RAP1GAP CD74	1.16e-04	200	56	4	1f99afa1f3c32a2a9cfb4ad33ff4d404e34fac63
Drug	haloperidol; Up 200; 10uM; PC3; HT_HG-U133A	SCN11A PTPRN2 DOCK9 DGKE GMPR ZNF362 NOS2	4.50e-07	196	55	7	4468_UP
Drug	Dexrazoxane	TOP2A TOP2B	5.73e-06	2	55	2	DB00380
Drug	AC1NSWD2	SYNE1 TOP2B	5.73e-06	2	55	2	CID005318091
Drug	F14512	TOP2A TOP2B	5.73e-06	2	55	2	ctd:C534191
Drug	Daunorubicin	TOP2A TOP2B	5.73e-06	2	55	2	DB00694
Drug	Metyrapone [54-36-4]; Up 200; 17.6uM; MCF7; HT_HG-U133A	SCN11A IGF1 CALCR RASA3 CD74 GMPR	6.64e-06	191	55	6	5667_UP
Drug	estradiol, USP; Up 200; 0.01uM; PC3; HT_HG-U133A	GLYAT SCN11A PTPRN2 DOCK9 DGKE GMPR	7.92e-06	197	55	6	4465_UP
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	IGF1 CALCR RASA3 SYNE1 ZFP64 CD74	8.15e-06	198	55	6	3970_UP
Drug	Glipizide [29094-61-9]; Up 200; 9uM; HL60; HG-U133A	GABRR2 FLNB RAP1GAP IQSEC1 APBA3 PID1	8.64e-06	200	55	6	2008_UP
Drug	luteolin	RAP1GAP IGF1 CD74 NOS2 TOP2B	1.61e-05	131	55	5	CID005280445
Drug	inositol pentaphosphate	IP6K3 IP6K1	1.72e-05	3	55	2	ctd:C013571
Drug	gramine	CALCR SYNE1 ALDH18A1	1.99e-05	22	55	3	CID000006890
Drug	rebamipide	IGF1 WEE1 NOS2 TOP2A	3.26e-05	75	55	4	ctd:C052785
Drug	alpha-viniferin	NOS2 TOP2B	3.43e-05	4	55	2	CID000196402
Drug	Dobutamine	IGF1 DMD CPT1A NOS2	3.81e-05	78	55	4	ctd:D004280
Drug	Metformin	CMBL RLF IGF1 ALDH18A1 GMPR CPT1A NOS2	4.81e-05	400	55	7	ctd:D008687
Drug	dimethoxyphenol	SYNE1 TOP2B	8.54e-05	6	55	2	CID000078828
Drug	chelirubine	CALCR SYNE1	8.54e-05	6	55	2	CID000161243
Drug	tiapamil	SYNE1 DMD	8.54e-05	6	55	2	CID000042106
Drug	AC1L2K2J	CPT1A TOP2B	8.54e-05	6	55	2	CID000073552
Drug	iBVE	PTPRN2 APC CPT1A	9.00e-05	36	55	3	CID000007992
Drug	Pramoxine hydrochloride [637-58-1]; Down 200; 12.2uM; PC3; HT_HG-U133A	RASA3 STXBP5L APC GMPR CPT1A	9.76e-05	191	55	5	3811_DN
Drug	Piperacetazine [3819-00-9]; Up 200; 9.8uM; MCF7; HT_HG-U133A	GABRR2 SCN11A CALCR STXBP5L ZNF362	9.76e-05	191	55	5	3574_UP
Drug	creatine	GLYAT IGF1 CALCR MYH13 DMD	1.03e-04	193	55	5	CID000000586
Drug	Clopamide [636-54-4]; Up 200; 11.6uM; PC3; HT_HG-U133A	SCN11A PTPRN2 APBA3 DGKE ZNF292	1.08e-04	195	55	5	6301_UP
Drug	Diphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; PC3; HT_HG-U133A	GABRR2 DOCK9 MAP3K20 APC CPT1A	1.08e-04	195	55	5	7318_UP
Drug	Gemfibrozil [25812-30-0]; Up 200; 16uM; PC3; HT_HG-U133A	GABRR2 SYNE1 MAP3K20 APC APBA3	1.08e-04	195	55	5	2113_UP
Drug	Etifenin [63245-28-3]; Up 200; 12.4uM; PC3; HT_HG-U133A	SCN11A DGKE GMPR ZNF362 DMD	1.10e-04	196	55	5	3998_UP
Drug	(-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; PC3; HT_HG-U133A	GABRR2 SCN11A APC CPT1A PID1	1.10e-04	196	55	5	5833_UP
Drug	Salbutamol [18559-94-9]; Up 200; 16.8uM; MCF7; HT_HG-U133A	SCN11A ZFP64 CD74 DGKE GMPR	1.10e-04	196	55	5	2306_UP
Drug	Gelsemine [509-15-9]; Up 200; 12.4uM; PC3; HT_HG-U133A	IGF1 STXBP5L APC ZNF362 CPT1A	1.13e-04	197	55	5	4097_UP
Drug	Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; PC3; HT_HG-U133A	SCN11A IGF1 PTPRD DOCK9 ZFP64	1.13e-04	197	55	5	3672_UP
Drug	Bromopride [4093-35-0]; Up 200; 11.6uM; PC3; HT_HG-U133A	SCN11A ZFP64 TAF7L GMPR DMD	1.13e-04	197	55	5	3719_UP
Drug	Ofloxacin [82419-36-1]; Up 200; 11uM; PC3; HT_HG-U133A	GABRR2 SCN11A DOCK9 ZNF362 NOS2	1.16e-04	198	55	5	3673_UP
Drug	16, 16-dimethylprostaglandin E2 methyl acetate solution; Down 200; 10uM; PC3; HT_HG-U133A	PTPRN2 WEE1 MAP3K20 APBA3 GMPR	1.16e-04	198	55	5	6592_DN
Drug	Liothyronine [6893-02-3]; Up 200; 6.2uM; MCF7; HT_HG-U133A	GABRR2 CALCR RASA3 DOCK9 DMD	1.16e-04	198	55	5	3324_UP
Drug	Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; PC3; HT_HG-U133A	DOCK9 APC GMPR CPT1A PID1	1.16e-04	198	55	5	6696_DN
Drug	Hydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; PC3; HT_HG-U133A	RASA3 DOCK9 GMPR CPT1A NOS2	1.16e-04	198	55	5	5789_UP
Drug	Karakoline [39089-30-0]; Up 200; 10.6uM; HL60; HT_HG-U133A	PTPRN2 SYNE1 IQSEC1 APBA3 PID1	1.18e-04	199	55	5	2203_UP
Drug	Methazolamide [554-57-4]; Down 200; 17uM; MCF7; HT_HG-U133A	FLNB RAP1GAP WEE1 IQSEC1 APBA3	1.18e-04	199	55	5	6268_DN
Drug	pramiracetam	CALCR NOS2	1.19e-04	7	55	2	CID000051711
Drug	prednisone acetate	IGF1 DMD	1.19e-04	7	55	2	CID000091438
Drug	(N)-methanocarba-2MeSADP	RAP1GAP IGF1	1.19e-04	7	55	2	ctd:C511689
Drug	lornoxicam	IGF1 NOS2	1.19e-04	7	55	2	ctd:C059451
Drug	Picotamide monohydrate [80530-63-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A	GABRR2 ZFP64 TAF7L APC GMPR	1.21e-04	200	55	5	6787_UP
Drug	nordihydroguaiaretic acid; Up 200; 1uM; PC3; HT_HG-U133A	SCN11A PTPRD CALCR DOCK9 TAF7L	1.21e-04	200	55	5	4447_UP
Drug	Ornidazole [16773-42-5]; Up 200; 18.2uM; MCF7; HT_HG-U133A	GLYAT GBF1 ZFP64 APC APBA3	1.21e-04	200	55	5	2272_UP
Drug	aluminum nitride	IGF1 PTPRD CALCR	1.24e-04	40	55	3	CID000090455
Drug	Phosphorus, Dietary	IGF1 CALCR TOP2A	1.54e-04	43	55	3	ctd:D016226
Drug	NSC 329246	SYNE1 NOS2	1.59e-04	8	55	2	CID000100067
Drug	nimesulide	APC GMPR RIMS1 NOS2	1.67e-04	114	55	4	CID000004495
Drug	Raloxifene Hydrochloride	GLYAT FLNB IGF1 DOCK9 MAP3K20 CD74 NOS2 TOP2A TOP2B	1.95e-04	857	55	9	ctd:D020849
Drug	homohypotaurine	CALCR APC	2.04e-04	9	55	2	CID000193060
Drug	Fce 26644	IGF1 TOP2B	2.04e-04	9	55	2	CID000132977
Drug	Gly-pro-glu	IGF1 ALDH18A1	2.04e-04	9	55	2	CID003080768
Drug	liriodenine	NOS2 TOP2B	2.04e-04	9	55	2	CID000010144
Disease	Malignant neoplasm of breast	FLNB RAP1GAP IGF1 PTPRD SYNE1 ZFP64 CD74 DGKE DMD CPT1A NOS2 TOP2A	4.25e-07	1074	54	12	C0006142
Disease	B cell deficiency (implicated_via_orthology)	TOP2A TOP2B	3.29e-06	2	54	2	DOID:2115 (implicated_via_orthology)
Disease	Bipolar Disorder	GLYAT GABRR2 IGF1 SYNE1 DOCK9 RIMS1 GRIN3A	2.54e-05	477	54	7	C0005586
Disease	Mammary Carcinoma, Human	IGF1 PTPRD SYNE1 CD74 CPT1A NOS2 TOP2A	4.66e-05	525	54	7	C4704874
Disease	Mammary Neoplasms, Human	IGF1 PTPRD SYNE1 CD74 CPT1A NOS2 TOP2A	4.66e-05	525	54	7	C1257931
Disease	Mammary Neoplasms	IGF1 PTPRD SYNE1 CD74 CPT1A NOS2 TOP2A	4.77e-05	527	54	7	C1458155
Disease	Breast Carcinoma	IGF1 PTPRD SYNE1 CD74 CPT1A NOS2 TOP2A	5.44e-05	538	54	7	C0678222
Disease	Autistic Disorder	IGF1 APC RIMS1 NOS2 ZNF292	1.16e-04	261	54	5	C0004352
Disease	retinopathy of prematurity (biomarker_via_orthology)	IGF1 NOS2	2.14e-04	12	54	2	DOID:13025 (biomarker_via_orthology)
Disease	acute myeloid leukemia (implicated_via_orthology)	TOP2A TOP2B	2.14e-04	12	54	2	DOID:9119 (implicated_via_orthology)
Disease	third ventricle volume measurement	GABRR2 PTPRD	3.40e-04	15	54	2	EFO_0010335
Disease	amenorrhea, response to antineoplastic agent	CALCR RIMS1	3.40e-04	15	54	2	EFO_0010269, GO_0097327
Disease	asparaginase hypersensitivity	IP6K3 CEP57L1 ERMARD	3.85e-04	77	54	3	EFO_0004881
Disease	Cardiovascular Abnormalities	NOS2 ZNF292	3.88e-04	16	54	2	C0243050
Disease	phosphorus measurement	RAP1GAP IP6K3	3.88e-04	16	54	2	EFO_0004861
Disease	post-traumatic stress disorder symptom measurement	PTPRD SYNE1 IP6K1	4.63e-04	82	54	3	EFO_0008535
Disease	Mechanical Allodynia	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C2936719
Disease	Allodynia	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0458247
Disease	Hyperalgesia, Secondary	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0751212
Disease	Hyperalgesia, Primary	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0751211
Disease	Hyperalgesia, Thermal	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0751214
Disease	Tactile Allodynia	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0751213
Disease	Hyperalgesia	SCN11A IGF1 NOS2	4.97e-04	84	54	3	C0020429
Disease	Attention deficit hyperactivity disorder	PTPRD ZNF292	8.84e-04	24	54	2	C1263846
Disease	Colitis	IGF1 NOS2	9.60e-04	25	54	2	C0009319
Disease	paracentral lobule volume measurement	STXBP5L DOCK9	9.60e-04	25	54	2	EFO_0010317
Disease	Streptozotocin Diabetes	IGF1 CPT1A NOS2	1.03e-03	108	54	3	C0038433
Disease	Diabetes Mellitus, Experimental	IGF1 CPT1A NOS2	1.03e-03	108	54	3	C0011853
Disease	Alloxan Diabetes	IGF1 CPT1A NOS2	1.03e-03	108	54	3	C0002152
Disease	intestinal permeability measurement	GRIN3A PID1	1.04e-03	26	54	2	EFO_0011031
Disease	conotruncal heart malformations	PTPRD CALCR IQSEC1	1.21e-03	114	54	3	MONDO_0016581
Disease	Intellectual Disability	ZNF142 SYNE1 IQSEC1 APC ZNF292	1.34e-03	447	54	5	C3714756
Disease	Colorectal Neoplasms	PTPRD SYNE1 APC ZNF292	1.66e-03	277	54	4	C0009404
Disease	Colorectal Carcinoma	PTPRD PTPRN2 SYNE1 APC DMD ZNF292	1.74e-03	702	54	6	C0009402
Disease	Grey matter density measurement	IP6K3 RASA3	1.78e-03	34	54	2	EFO_0010306

Protein segments in the cluster

Peptide	Gene	Start	Entry
KMRETHEAESHMYLK	CALCR	326	P30988
MMDHALHTISYTADI	APBA3	286	O96018
ASEKHQHMYRLAMTG	CPT1A	636	P50416
KDQFHTHEGYMMDLT	DMD	376	P11532
DETMKLAGMHYLHVT	RASA3	381	Q14644
TSAHVMSMGLLHFYK	ODF4	126	Q2M2E3
STGHMILSYMEDHLK	PTPRN2	726	Q92932
VTIMDHHSAAESFMK	NOS2	431	P35228
HGMDHRKLDEMTASY	IQSEC1	286	Q6DN90
EMFKLSSMDVTHAHL	GLYAT	166	Q6IB77
SKLAGFIMKEIMYHH	FSIP2	5221	Q5CZC0
TEVGLHEMHIKYMGS	FLNB	1791	O75369
HEMHIKYMGSHIPES	FLNB	1796	O75369
LAHAMMEAFRKTFHS	PID1	211	Q7Z2X4
GGHMSVMKYDEHTVC	IP6K3	26	Q96PC2
MKTSMESLIHHFKLY	NDUFS2	371	O75306
VMGHSEGICHMYVDS	ALDH18A1	576	P54886
ISQYKSHGFMDMLHD	GRIN3A	891	Q8TCU5
MKSTSVSGEMYTLEH	RIMS1	1396	Q86UR5
YEKMMTSHGHLEDLQ	B3GNT5	316	Q9BYG0
HIQMKVMSYSEDHRS	BSND	116	Q8WZ55
KYLKSLHAMEGHVMI	DOCK9	851	Q9BZ29
YTKSFVKHSMEHVSM	CCNL2	111	Q96S94
ATDVAKGMHYLHMEA	MAP3K20	111	Q9NYL2
HSSMMRYDDHTVCKP	IP6K1	36	Q92551
MDKYMHAGSSDLLSE	GBF1	1651	Q92538
MDSELMHSIVGSYHK	CEP57L1	1	Q8IYX8
KVKMHTMSSSHLFYL	IGF1	21	P05019
HSLITKMTDELYHHM	ERMARD	476	Q5T6L9
ATKYGNMTEDHVMHL	CD74	131	P04233
TVTITHKTHAMMLYF	DGKE	531	P52429
HKTHAMMLYFSGEQT	DGKE	536	P52429
VMSQHSMFTAIHKHY	GMPR	66	P36959
HSSAAMLKIAEMEYS	BYSL	321	Q13895
HSKTMMLDGSYSESE	GABRR2	371	P28476
AVMEHAESKMYATSP	PTPRD	1231	P23468
HSIEMHLPYTAKAME	MEMO1	131	Q9Y316
MSSHKQGHTSSEYDM	TAF7L	306	Q5H9L4
SAYHHGEQALMMTIV	TOP2B	776	Q02880
MTDAIHMLDSYCHPT	SYNE1	3296	Q8NF91
TLYEELHIHSQSMMG	RAP1GAP	396	P47736
DMLSSHHYKSFKVSM	MAPKAP1	376	Q9BPZ7
MTSAEAFSKHAHELM	STXBP5L	1161	Q9Y2K9
YSLLSMLGTHDKDDM	APC	316	P25054
TAVHHLMMKYSEFRA	CMBL	136	Q96DG6
THHTKMMLLLYEEGL	TDP1	261	Q9NUW8
YIHSMSLVHMDIKPS	WEE1	416	P30291
HHSKMHMEDGIYTCP	RLF	571	Q13129
YGSMSMSFEAHHLTV	SPO11	291	Q9Y5K1
ITGLIQHYMKLHEMT	ZNF292	2186	O60281
ETKTPGVMDHYLVMH	MYH13	681	Q9UKX3
VAEMSSYHHGEMSLM	TOP2A	751	P11388
SYHHGEMSLMMTIIN	TOP2A	756	P11388
TSETYLMKHMSKHTV	ZNF362	381	Q5T0B9
HVNFSHLTTKDYMEM	SLC6A17	391	Q9H1V8
TVFLAMEHHKMEASF	SCN11A	591	Q9UI33
KHMLTHSNTKDYMCT	ZNF142	446	P52746
AYGMKDMERHLKIHT	ZFP64	156	Q9NTW7
TFHEGKHNISHMSMD	WDFY1	361	Q8IWB7